Please assess the completion status of the following clinical trial:

Trial Title: Improving Communication in Older Cancer Patients and Their Caregivers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria for Patients~* Male or female 70 years of age or older~* Diagnosis of an advanced solid tumor malignancy (advanced cancer) or lymphoma. In most situations, this would be a stage IV cancer. A patient with a diagnosis of stage III cancer or lymphoma is eligible if cure is not possible or anticipated. Clinical staging without pathological confirmation of advanced disease is allowed.~* Must be considering or currently receiving any kind of cancer treatment (any line), including but not limited to hormonal treatment, chemotherapy, monoclonal antibody therapy, or targeted therapy. Patients who are considering therapy are eligible even if they ultimately choose not to be on therapy. Patients with a history of any previous cancer treatment, including radiation and/or surgery are eligible. A patient may also be enrolled on a treatment trial and participate in this study, if all other inclusion and exclusion criteria are met.~* Have at least one geriatric assessment domain meet the cut-off score for impairment other than polypharmacy.~* Have visits planned with the oncology physician for at least 3 months and be willing to come in for study visits.~* Able to provide informed consent or, if the oncology physician determines the patient to not have decision-making capacity, a patient-designated health care proxy (per institutional policies) must sign consent by the baseline visit.~* Subject has adequate understanding of the English language because not all GA measures have been validated in other languages.~Exclusion Criteria for Patients~* Have surgery planned within 3 months of consent. Patients who have previously received surgery are eligible.~* Have already made a decision to not undergo any cancer treatment (e.g., being followed in best supportive care or hospice).~Inclusion Criteria for Caregivers~* Selected by the patient when asked if there is a family member, partner, friend or caregiver \[age 21 or older\] with whom you discuss or who can be helpful in health-related matters; patients who cannot identify such a person (caregiver) can be eligible for the study. A caregiver need not be someone who lives with the patient or provides direct hands-on care. A caregiver can be any person who provides support (in any way) to the patient.~* If a health care proxy signs consent for or with a patient, and wants to participate in the caregiver portion of the study, this same person will always be the caregiver selected. If a health care proxy does not want to enroll as a caregiver in the study or, if enrolled, chooses to stop their own participation in the caregiver portion of the study, but is able to assist the patient in completing the study, the patient can still participate. In other words, the health care proxy can choose NOT to participate in the caregiver portion of the study. This does not preclude the patient from participating in the patient portion of the study with the health care proxy's assistance.~Exclusion Criteria for Caregivers~-Caregivers unable to understand the consent form due to cognitive, health, or sensory impairment will be excluded.

- Gender: ALL
- Minimum Age: 70 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Arm I: Geriatric Assessment Intervention (Type: EXPERIMENTAL): At the first study visit with their oncologist, patients and their caregivers (if participating) complete the GA and receive the intervention; GA summary plus GA targeted recommendations which is provided to the oncology team to discuss and implement if they so choose.
- Arm II: Usual Care (Type: ACTIVE_COMPARATOR): At the first study visit with their oncologist, patients and their caregivers (if participating) complete the GA (no GA summary or recommendations are provided).

Based on this trial design, predict the completion outcome and termination type (if applicable).